Skip to main content

Higgins John L's Form 4 filing

BIO-TECHNE Corp (TECH) · filed Jun 9, 2022

Accession no.
0001415889-22-006392
Filed
Jun 9, 2022
Trade date
Jun 7-8, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $584.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Higgins John LCIK 0001208906Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 7, 2022Common StockMOption exerciseAcquired+1,000$66.90+$66,9005,606Direct
Jun 7, 2022Common StockSSaleDisposed−1,000$364.31F1−$364,3104,606Direct
Jun 8, 2022Common StockMOption exerciseAcquired+600$66.90+$40,1405,206Direct
Jun 8, 2022Common StockSSaleDisposed−600$366.09F2−$219,6544,606Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 7, 2022Common StockMOption exerciseDisposed−5,000$0.00$04,000Direct
Jun 8, 2022Common StockMOption exerciseDisposed−4,000$0.00$03,400Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 364.0000 to 364.6400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 366.0000 to 366.1900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)